Patent US4816449A successfully refreshed from Google Patents.
US4816449A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunotherapeutic anti-inflammatory peptide agents
Assignee: IMMUNETECH PHARMACEUTICALS A CORP OF
•
Filing: 1986-12-09
•
Granted: 1989-03-28
•
Expires: 2006-12-09
Abstract
Abstract Anti-inflammatory peptides of the formula A-B-C-D-E, useful in treating allergies, autoimmune diseases, and other disorders, and methods for using them are described.
Inventors
- 👤 Gary S. Hahn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 17:54
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/04; C07K5/08; C07K5/0819; A; A61; A61P; A61P29/00; A61P37/00; A61P37/08; A61P43/00; C07K16/00; C07K5/10; C07K5/1002; C07K5/1005; C07K5/1008; C07K5/1013; C07K5/1021; C07K5/1024; A61K; A61K38/00
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
60 words
An anti-inflammatory peptide having an amino acid sequence A-B-C-D-E wherein A is Asp or Glu; B is Ser, D-Ser, Thr, Ala, Gly, or Sarcosine; C is Asp, Glu, Asn, or Gln; D is Pro, Val, Ala, Leu, or Ile; and E is Arg, Lys, or Orn and pharmaceutically acceptable salts thereof, provided that Asp-Ser-Glu-Pro-Arg, Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, and Asp-Thr-Glu-Ala-Arg are excluded.
Claim 2
Dependent Claim
60 words
An anti-inflammatory peptide having an amino acid sequence A-B-C-D-E wherein A is Asp or Glu; B is Ser, D-Ser, Thr, Ala, Gly, or Sarcosine; C is Asp, Glu, Asn, or Gln; D is Pro, Val, Ala, Leu, or Ile; and E is Arg, Lys, or Orn and pharmaceutically acceptable salts thereof, provided that Asp-Ser-Glu-Pro-Arg, Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, and Asp-Thr-Glu-Ala-Arg are excluded.
Claim 3
Independent Claim
74 words
A method of reducing an inflammatory response in a mammal, comprising administering an effective amount of a peptide having an amino acid sequence A-B-C-D-E wherein A is Asp or Glu; B is Ser, D-Ser, Thr, Ala, Gly, or Sarcosine; C is Asp, Glu, Asn, or Gln; D is Pro, Val, Ala, Leu, or Ile; and E is Arg, Lys, or Orn and pharmaceutically acceptable salts thereof, provided that Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, and Asp-Thr-Glu-Ala-Arg are excluded.
Claim 4
Independent Claim
74 words
A method of reducing an inflammatory response in a mammal, comprising administering an effective amount of a peptide having an amino acid sequence A-B-C-D-E wherein A is Asp or Glu; B is Ser, D-Ser, Thr, Ala, Gly, or Sarcosine; C is Asp, Glu, Asn, or Gln; D is Pro, Val, Ala, Leu, or Ile; and E is Arg, Lys, or Orn and pharmaceutically acceptable salts thereof, provided that Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, and Asp-Thr-Glu-Ala-Arg are excluded.
Claim 5
Independent Claim
82 words
A method of blocking immunoglobulin binding to basophil Fc receptors, comprising administering an effective amount to block immunoglobulin binding to basophil Fc receptors of a peptide having an amino acid sequence A-B-C-D-E wherein A is Asp or Glu; B is Ser, D-Ser, Thr, Ala, Gly, or Sarcosine; C is Asp, Glu, Asn, or Gln; D is Pro, Val, Ala, Leu, or Ile; and E is Arg, Lys, or Orn and pharmaceutically acceptable salts thereof, provided that Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, and Asp-Thr-Glu-Ala-Arg are excluded.
Claim 6
Independent Claim
82 words
A method of blocking immunoglobulin binding to basophil Fc receptors, comprising administering an effective amount to block immunoglobulin binding to basophil Fc receptors of a peptide having an amino acid sequence A-B-C-D-E wherein A is Asp or Glu; B is Ser, D-Ser, Thr, Ala, Gly, or Sarcosine; C is Asp, Glu, Asn, or Gln; D is Pro, Val, Ala, Leu, or Ile; and E is Arg, Lys, or Orn and pharmaceutically acceptable salts thereof, provided that Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, and Asp-Thr-Glu-Ala-Arg are excluded.
Claim 7
Independent Claim
84 words
A method of blocking immune complex binding to immunoglobulin Fc receptors, comprising administering an effective amount to reduce immune complex mediated inflammation or tissue destruction of a peptide having an amino acid sequence A-B-C-D-E wherein A is Asp or Glu; B is Ser, D-Ser, Thr, Ala, Gly, or Sarcosine; C is Asp, Glu, Asn, or Gln; D is Pro, Val, Ala, Leu, or Ile; and E is Arg, Lys, or Orn and pharmaceutically acceptable salts thereof, provided that Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, and Asp-Thr-Glu-Ala-Arg are excluded.
Claim 8
Independent Claim
84 words
A method of blocking immune complex binding to immunoglobulin Fc receptors, comprising administering an effective amount to reduce immune complex mediated inflammation or tissue destruction of a peptide having an amino acid sequence A-B-C-D-E wherein A is Asp or Glu; B is Ser, D-Ser, Thr, Ala, Gly, or Sarcosine; C is Asp, Glu, Asn, or Gln; D is Pro, Val, Ala, Leu, or Ile; and E is Arg, Lys, or Orn and pharmaceutically acceptable salts thereof, provided that Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, and Asp-Thr-Glu-Ala-Arg are excluded.
Claim 9
Dependent Claim
11 words
An anti-inflammatory peptide according to claim 1 wherein A is Asp.
Claim 10
Dependent Claim
11 words
An anti-inflammatory peptide according to claim 1 wherein B is Ser.
Claim 11
Dependent Claim
11 words
An anti-inflammatory peptide according to claim 1 wherein C is Asp.
Claim 12
Dependent Claim
11 words
An anti-inflammatory peptide according to claim 1 wherein D is Pro.
Claim 13
Dependent Claim
11 words
An anti-inflammatory peptide according to claim 1 wherein E is Arg.
Claim 14
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein A is Asp and B is Ser.
Claim 15
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein A is Asp and B is D-Ser.
Claim 16
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein A is Asp and C is Asp.
Claim 17
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein A is Asp and D is Pro.
Claim 18
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein A is Asp and E is Arg.
Claim 19
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein B is Ser and C is Asp.
Claim 20
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1, wherein B is D-Ser and C is Asp.
Claim 21
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein B is Ser and D is Pro.
Claim 22
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1, wherein B is D-Ser and D is Pro.
Claim 23
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein B is Ser and E is Arg.
Claim 24
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein C is Asp and D is Pro.
Claim 25
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein C is Asp and E is Arg.
Claim 26
Dependent Claim
15 words
An anti-inflammatory peptide according to claim 1 wherein D is Pro and E is Arg.
Claim 27
Dependent Claim
88 words
An anti-inflammatory peptide according to claim 1 wherein said peptide is selected from the group consisting of Glu-Ser-Asp-Pro-Arg, Asp-Thr-Asp-Pro-Arg, Glu-Thr-Asp-Pro-Arg, Asp-Ala-Asp-Pro-Arg, Glu-Ala-Asp-Pro-Arg, Glu-Ser-Glu-Pro-Arg, Asp-Thr-Glu-Pro-Arg, Glu-Thr-Glu-Pro-Arg, Asp-Ala-Glu-Pro-Arg, Glu-Ala-Glu-Pro-Arg, Asp-Ser-Asp-Val-Arg, Glu-Ser-Asp-Val-Arg, Asp-Thr-Asp-Val-Arg, Glu-Thr-Asp-Val-Arg, Asp-Ala-Asp-Val-Arg, Glu-Ala-Asp-Val-Arg, Asp-Ser-Glu-Val-Arg, Glu-Ser-Glu-Val-Arg, Asp-Thr-Glu-Val-Arg, Glu-Thr-Glu-Val-Arg, Asp-Ala-Glu-Val-Arg, Glu-Ala-Glu-Val-Arg, Asp-Ser-Asp-Ala-Arg, Glu-Ser-Asp-Ala-Arg, Asp-Thr-Asp-Ala-Arg, Glu-Thr-Asp-Ala-Arg, Asp-Ala-Asp-Ala-Arg, Glu-Ala-Asp-Ala-Arg, Asp-Ser-Glu-Ala-Arg, Glu-Ser-Glu-Ala-Arg, Asp-Thr-Glu-Ala-Arg, Glu-Thr-Glu-Ala-Arg, Asp-Ala-Glu-Ala-Arg, Glu-Ala-Glu-Ala-Arg, Asp-Ser-Asp-Pro-Lys, Glu-Ser-Asp-Pro-Lys, Asp-Thr-Asp-Pro-Lys, Glu-Thr-Asp-Pro-Lys, Asp-Ala-Asp-Pro-Lys, Glu-Ala-Asp-Pro-Lys, Asp-Ser-Glu-Pro-Lys, Glu-Ser-Glu-Pro-Lys, Asp-Thr-Glu-Pro-Lys, Glu-Thr-Glu-Pro-Lys, Asp-Ala-Glu-Pro-Lys, Glu-Ala-Glu-Pro-Lys, Asp-Ser-Asp-Val-Lys, Glu-Ser-Asp-Val-Lys, Asp-Thr-Asp-Val-Lys, Glu-Thr-Asp-Val-Lys, Asp-Ala-Asp-Val-Lys, Glu-Ala-Asp-Val-Lys, Asp-Ser-Glu-Val-Lys, Glu-Ser-Glu-Val-Lys, Asp-Thr-Glu-Val-Lys, Glu-Thr-Glu-Val-Lys, Asp-Ala-Glu-Val-Lys, Glu-Ala-Glu-Val-Lys, Asp-Ser-Asp-Ala-Lys, Glu-Ser-Asp-Ala-Lys, Asp-Thr-Asp-Ala-Lys, Glu-Thr-Asp-Ala-Lys, Asp-Ala-Asp-Ala-Lys, Glu-Ala-Asp-Ala-Lys, Asp-Ser-Glu-Ala-Lys, Glu-Ser-Glu-Ala-Lys, Asp-Thr-Glu-Ala-Lys, Glu-Thr-Glu-Ala-Lys, Asp-Ala-Glu-Ala-Lys, and Glu-Ala-Glu-Ala-Lys.
Claim 28
Dependent Claim
41 words
An anti-inflammatory peptide according to claim 1, wherein said peptide is selected from the group consisting of Asp-D-Ser-Asp-Pro-Arg Glu-D-Ser-Asp-Pro-Arg Asp-D-Ser-Glu-Pro-Arg Glu-D-Ser-Glu-Pro-Arg Asp-D-Ser-Asp-Val-Arg Glu-D-Ser-Asp-Val-Arg Asp-D-Ser-Glu-Val-Arg Glu-D-Ser-Glu-Val-Arg Asp-D-Ser-Asp-Ala-Arg Glu-D-Ser-Asp-Ala-Arg Asp-D-Ser-Glu-Ala-Arg Glu-D-Ser-Glu-Ala-Arg Asp-D-Ser-Asp-Pro-Lys Glu-D-Ser-Asp-Pro-Lys Asp-D-Ser-Glu-Pro-Lys Glu-D-Ser-Glu-Pro-Lys Asp-D-Ser-Asp-Val-Lys Glu-D-Ser-Asp-Val-Lys Asp-D-Ser-Glu-Val-Lys Glu-D-Ser-Glu-Val-Lys Asp-D-Ser-Asp-Ala-Lys Glu-D-Ser-Asp-Ala-Lys Asp-D-Ser-Glu-Ala-Lys Glu-D-Ser-Glu-Ala-Lys.
Claim 29
Dependent Claim
19 words
An anti-inflammatory peptide according to claim 1 wherein said peptide is an amino-terminal acetyl derivative of the form Ac-A-B-C-D-E.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-03-27 | 1992-09-26 | 1993-03-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-03-27 | 1996-09-26 | 1997-03-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-03-27 | 2000-09-26 | 2001-03-28 | $7700.00 | Window Closed / Lapsed |